ReviewCurrent pharmaceutical design2013
Agonist replacement for stimulant dependence: a review of clinical research.
Review in Current pharmaceutical design, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.Psychopharmacology · 2020Pooled it
- Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial.Molecular psychiatry · 2017Trial
- Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Unpredictable Drug Access and its Relevance for Substance Use Disorders: A Critical Review.Perspectives on behavior science · 2025Review
- Emerging medications and pharmacological treatment approaches for substance use disorders.Pharmacology, biochemistry, and behavior · 2025Review
- Methylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.Substance abuse and rehabilitation · 2024Review
- Choice between food and cocaine or fentanyl reinforcers under fixed and variable schedules in female and male rhesus monkeys.Psychopharmacology · 2023Article
- Environmental Uncertainty and Substance Use Disorders: A Behavior Analytic Perspective.Policy insights from the behavioral and brain sciences · 2023Article
- Review
- Dopamine Supersensitivity: A Novel Hypothesis of Opioid-Induced Neurobiological Mechanisms Underlying Opioid-Stimulant Co-use and Opioid Relapse.Frontiers in psychiatry · 2022Review
- Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?Addiction (Abingdon, England) · 2021Article
- Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Effects of chronic treatment with bupropion on self-administration of nicotine + cocaine mixtures in nonhuman primates.Experimental and clinical psychopharmacology · 2020Article
- Opening the cocaine economy by providing within-session access to a cheaper source of cocaine makes demand for it more elastic.Behavioural pharmacology · 2020Article
- Further pharmacological comparison of D-methamphetamine and L-methamphetamine in rats: abuse-related behavioral and physiological indices.Behavioural pharmacology · 2019Article
- Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.Pharmacology, biochemistry, and behavior · 2018Review
- Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: Association of bupropion and stimulant use disorder remission.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2018Article
- Minding the brain: the role of pharmacotherapy in substance-use disorder treatment.Dialogues in clinical neuroscience · 2017Review
- Novel nanoformulation to mitigate co-effects of drugs of abuse and HIV-1 infection: towards the treatment of NeuroAIDS.Journal of neurovirology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Stimulant use disorders are an unrelenting public health concern worldwide. Agonist replacement therapy is among the most effective strategies for managing substance use disorders including nicotine and opioid dependence. The present paper reviewed clinical data from human laboratory self-administration studies and clinical trials to determine whether agonist replacement therapy is a viable strategy for managing cocaine and/or amphetamine use disorders. The extant literature suggests that agonist replacement therapy may be effective for managing stimulant use disorders, however, the clinical selection of an agonist replacement medication likely needs to be based on the pharmacological mechanism of the medication and the stimulant abused by patients. Specifically, dopamine releasers appear most effective for reducing cocaine use whereas dopamine reuptake inhibitors appear most effective for reducing amphetamine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.